The Oral Microbiome in Pediatric IBD: A Source of Pathobionts or Biomarkers?

Khalid Elmaghrawy¹, Séamus Hussey²,³ and Gary P. Moran¹*

¹ School of Dental Science, Trinity College Dublin and Dublin Dental University Hospital, Dublin, Ireland, ² Department of Paediatrics, University of Medicine and Health Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland, ³ National Children’s Research Centre, Dublin, Ireland

The oral cavity is continuous with the gastrointestinal tract and in children, oral health may be closely linked with the overall health of the GI tract. In the case of pediatric Crohn’s disease (CD), oral manifestations are an important clinical indicator of intestinal disease. Recent studies of the microbiome in IBD suggest that translocation of oral microbes to the gut may be a common feature of the microbial dysbiosis which is a signature of both CD and ulcerative colitis (UC). Murine studies suggest that translocation of oral bacteria and yeasts to the lower GI tract may trigger inflammation in susceptible hosts, providing a mechanistic link to the development of IBD. Conversely, some studies have shown that dysbiosis of the oral microbiome may occur, possibly as a result of inflammatory responses and could represent a useful source of biomarkers of GI health. This review summarizes our current knowledge of the oral microbiome in IBD and presents current hypotheses on the potential role of this community in the pathogenesis of these diseases.

Keywords: inflammatory bowel disease, Crohn’s disease, ulcerative colitis, microbiome, dysbiosis, inflammation, oral cavity

INTRODUCTION

In the human body, microbial cells are thought to be at least as numerous as host cells (1–4). The microbiome of the human digestive tract is made up of hundreds of bacterial and fungal species and these microbes harbor 150 times more genes compared to the human genome (5, 6). Microbial population densities in this complex consortium reach their maximum values in the colon, with \(10^{11}\) bacteria per gram of content (4). The gut microbiota play a critical role in human health and have been implicated in nutrient absorption, mucosal barrier fortification, xenobiotic metabolism, angiogenesis and postnatal intestinal maturation (7, 8). Furthermore, the human microbiota stimulates immunity (innate and adaptive) and plays an important role in maturation of the immune system (9). Additionally, studies in germ-free mice show that gut microbiota influence body fat deposition, metabolism, and immune function (10, 11). Recent studies suggest that IBD is the result of an altered immune response to the gut microbiota (12). Perturbations in the microbiome may lead to dysbiosis which can be defined as “changes to the structure of a microbial community that are detrimental to its host” (13). This may impair important functions of the microbiome, including its ability to resist pathogenic microorganisms. In the oral cavity, microbiome perturbations caused by increased sugar intake or poor oral hygiene may lead to dental caries and inflammatory gum diseases, respectively (14, 15). Changes to the human gut microbiome have been linked with the prevalence and severity of several diseases, including cancers, IBD.
and atopic disease (5, 7). The role of the microbiome in the
pathogenesis of IBD is still hotly debated, but the disease
involves a strong inflammatory response that may be triggered
by acquired infection or alternatively by dysbiotic changes
to the hosts’ own microbiome. In the case of CD, the trigger
for this breakdown in homeostasis is unknown, but recent evidence
suggests that environmental factors, host genetics and possibly
oral-gut transit of microorganisms could all play a role in
perturbation of the relationship between the mucosal immune
system and the gut microbiota (16, 17).

DEVELOPMENT OF THE ORAL AND GUT
MICROBIOMES IN CHILDREN

Most of the microbial biodiversity in the human microbiome
can be found in the GI tract, and in particular the oral and
gut microbiomes (1). However, in terms of composition, these
two communities are very distinct. The oral cavity is dominated
by facultative, sugar fermenting organisms (e.g., Streptococcus
and Actinomyces spp.) whereas the gut is dominated by a
metabolically diverse community of anaerobic bacteria (e.g.,
Clostridium and Bacteroides spp.) (1, 18). Although these
communities have distinct compositions, the level of species
richness is similar in both environments and a single individual
may harbor over 100 distinct species at each site (1). Interestingly,
the oral microbiome exhibits less interindividual variation
compared to the gut microbiome (1). The greater interindividual
variation observed in gut microbiomes appears to be related to
the greater impact of factors such as diet and antibiotic usage on
these communities, whereas the oral microbiome appears to be
more resilient to these challenges (11, 19–21). Both communities
are relatively stable over time in healthy individuals (1).

The development and maturation of the gut microbiome in infancy is influenced by several factors, including mode of
delivery, type of feeding and antibiotic usage (22) (Figure 1).
Disturbances to this development have been linked to obesity and
atopic disease, suggesting that development of this microbiome
has a strong impact on immune maturation and metabolism
(23, 24). Some of this regulatory activity has been related to
bacterial metabolites including short chain fatty acids (SCFAs)
such as acetate, propionate and butyrate. SCFAs are not only
an important source of nutrients for enterocytes but also induce
differentiation of regulatory T cells (Tregs) which have a central
role in the suppression of inflammatory and allergic responses (9,
25, 26). Nutrition also plays an important role in gut microbiome
development. In early life, infant breast feeding is associated
with reduced biodiversity and high levels of Bifidobacterium
species capable of metabolizing human milk oligosaccharides
(HMOs) (27). The introduction of solid food later results in
an increase in biodiversity and the capacity to metabolize more
complex carbohydrates. Children exposed to antibiotics display
delayed gut microbiome maturation, especially if administered
in the first 12 months of life and this can lead to increased
levels of Enterobacteriaceae and Bacteroidetes (27, 28). The gut
microbiome stabilizes at approximately 3 years of age, but diet
continues to have a major influence on composition in childhood
and later life. Children consuming western diets rich in fats
and low in fiber exhibit increased levels of Bacteroides species,
whereas plant and fiber rich diets are associated with Prevotella
and Succinivibrio (29–31). In general, fat-rich western diets may
lead to reduced biodiversity and lower production of SCFAs,
which may impact on the development of inflammatory bowel
disease (32, 33).

The oral microbiome also develops and matures throughout
childhood. The mature oral microbiome is a highly diverse
community of up to 700 bacterial species, in addition to
the oral fungal mycobiome which is dominated by the yeasts
Candida, Malassezia and Saccharomyces spp. (18, 34–36). The
development of this oral microbiome begins shortly after birth
and recent data shows that this is also influenced by delivery
method and infant feeding (37). Diversity increases with tooth
eruption and continues to evolve as children move from
deciduous to permanent dentition (37, 38). Sugar intake and

![FIGURE 1](image-url)

**FIGURE 1** | Factors affecting the development of the oral and gut microbiomes in childhood. Evidence shows that both oral and gut microbiomes are influenced by delivery (natural or cesarean), mode of feeding (breast or formula milk) and antibiotics. Genetics may also play a role in colonization. Development of the gut microbiome is heavily influenced by diet whereas sugar intake (especially frequent consumption) has a greater impact on the oral microbiome. In the oral environment, tooth eruption and the level of plaque development (impacted by hygiene and saliva flow) have a major impact on diversity.
poor oral hygiene have a major impact on the oral microbiome in children (19, 39). Sugar intake in particular is linked to increased levels of acid tolerant species such as *S. mutans* and *Lactobacillus* spp. (19, 40), the former being directly linked with the pathogenesis of dental caries. Other dietary factors such as vegetables and refined grain servings have more moderate effects (37, 41). Antibiotic usage in childhood has been shown to affect the oral microbiome, however studies in adults suggest that the oral microbiome recovers more rapidly from antibiotic exposure compared to gut communities (20, 37).

**ORAL AND GUT MANIFESTATIONS OF IBD**

Crohn’s disease (CD) and Ulcerative colitis (UC) manifest in different ways. CD is typically characterized by granulomatous inflammation that can affect any part of the gastrointestinal tract (GIT) and involve all mucosal layers, while the inflammation in UC is limited to the colon and only affects the mucosa and superficial submucosa (42–44). The variability in location and the transmural nature of CD leads to a wide variety of presentations and in severe cases, patients may present with systemic symptoms, including fever, anorexia, and weight loss (45, 46). Inflammation in CD most frequently affects the distal ileum and colon but may occur in any part of the gastrointestinal tract including the mouth (47). The term oral Crohn’s disease (OCD) is used to describe patients with intestinal CD who exhibit involvement of the oral cavity with a wide variety of disease-specific oral lesions (48). Many oral lesions have been described in CD patients, including swelling of the lips, buccal mucosal swelling or “cobble-stoning,” mucogingivitis, deep linear ulceration, particularly along the buccal gutters, and mucosal tags. Submental lymphadenopathy, perioral erythema with scaling, recurrent buccal abscesses, and angular cheilitis are often observed in patients with CD (43, 48). The oral manifestations of IBD are diverse and based on their relationship with CD activity can be classified as specific (e.g., mucosal swelling) and non-specific oral lesions (e.g., angular cheilitis) (49). Similar oral manifestations have been recorded in different patient cohorts throughout the world (47–52). Although patients with CD can exhibit oral manifestations, pediatric CD has no specific clinical manifestations. Some studies have suggested that oral manifestations are a good cutaneous marker of IBD (50) and are useful diagnostic markers (53).

Orofacial granulomatosis (OFG) is a rare chronic disease that can present with symptoms similar to oral Crohn’s disease, including lip swelling and oral inflammation (54). Despite the clinical similarity, OFG patients rarely present with clinical signs of intestinal CD and it is not known if the etiology of OFG is related to that of CD (54). OFG patients have a high incidence of atopy and some studies have suggested the involvement of IgE expressing B-cells in the development of the disease, suggesting that this may involve a hypersensitivity reaction (55, 56).

**THE GUT MICROBIOME IN IBD**

Significant alterations to the gut and oral microbiomes (discussed below) have been identified in patients with IBD, including both CD and UC patients (12, 17, 51, 57–62). Microbial dysbiosis in the gut of IBD patients has been associated with the generation of a chronic inflammatory response which may be exacerbated by a decrease in community members known to produce immunomodulating SCFAs and increased levels of the *Enterobacteriaceae* (57, 63, 64). Within the last decade, metagenomic profiling microbiome studies have provided detailed information on this dysbiosis and unexpectedly have identified increased abundance of common oral taxa in the gut microbiomes of patients with IBD (e.g., *Veillonella, Haemophilus, Eikenella* spp.) whereas many bacteria with important roles in the generation of SCFAs were reduced (59, 62, 65). An increased H₂S producers in IBD patients was also noted by Mottawea et al. (2016), which was linked to a reduced capacity of mitochondria from IBD patients to detoxify H₂S, suggesting an additional mechanism for microbiome induced inflammation (60). Studies have shown that this dysbiosis is dynamic and is greatest in patients with severe disease and those with a history of antibiotic usage (59). Medications such as infliximab can also influence the degree of dysbiosis (66–68). The degree of dysbiosis has also been linked to host genetics, with NOD2 risk alleles being shown to be associated with the degree of dysbiosis and the levels of *Enterobacteriaceae* in IBD patients (69, 70).

Changes in the fungal mycobiome have also been reported in IBD patients (71, 72). Fungi are often overlooked because of their low abundance in the lower GIT of humans, however, fungi account for approximately 13% of the gut microbial volume (6, 73). Several investigators have shown an increase in the levels of fungi belonging to the Basidiomycota in IBD patients, including the yeasts of the genus *Malassezia* (74–76). Limon et al. (2019) found that the presence of the *Malassezia* spp. in CD showed strong linkage to an allele of the CARD9 receptor (CARD9<sup>Y102N</sup>) associated with CD (76). They went on to demonstrate that *M. restricta* could induce colitis in susceptible mice, providing the first evidence that a member of the normal mycobiome may play a role in the pathogenesis of CD in at least a subset of patients (76).

In summary, the gut microbiome in pediatric IBD is now well-characterized. Several longitudinal, large cohort studies involving treatment naïve patients have clearly shown that changes to the gut microbiome are intrinsically linked to IBD and are responsive to therapy (59, 62, 65). This dysbiosis appears to be associated with reduced biodiversity and reduced levels of normal gut microbes with increases in the levels of *Enterobacteriaceae* and bacterial and yeast species normally associated with the oral cavity (e.g., *Veillonella, Haemophilus, Eikenella* and *Malassezia* spp.).

**CHANGES IN THE ORAL MICROBIOTA IN PATIENTS WITH CROHN’S DISEASE**

A general feature of the studies described above is the identification of high levels of oral taxa in the gut of IBD patients. The oral microbiome is well-characterized in terms of its role in oral diseases (caries, periodontitis), however its members have also been implicated as contributory factors in several non-oral diseases such as colorectal cancer, diabetes
mellitus, cardiovascular disease, bacteremia and preterm birth (77). Relatively few studies have directly investigated the impact of IBD on the oral microbiome in pediatric patients. The first analysis of the oral microbiome in pediatric IBD was carried out using DNA microarrays (51). In this study oral swab samples from the tongue and buccal mucosa of pediatric CD patients on active treatments were examined. Although the species-resolution of DNA microarray analysis is weak compared to more recent sequence based approaches, it was found that the overall microbiome biodiversity of CD patients was significantly reduced compared to healthy children. The tongue samples from pediatric CD patients showed reduced levels of two phyla (Fusobacteria and Firmicutes) and additionally, CD patients with oral manifestations were also shown to have a higher level of anti-Saccharomyces cerevisiae antibody (ASCA) (51).

More recently, 16S sequence based approaches have been used to examine the salivary microbiome in IBD. Said et al. (2014) analyzed the salivary microbiome of adult IBD patients (n = 35) including both CD and UC patients (61). Significant shifts in the oral microbiome composition of adult CD patients were observed, with higher levels of Prevotella and Veillonella spp. and reduced Streptococcus and Haemophilus spp. (61). Furthermore, a study by Xun et al. (2018) also examined the salivary microbiome in adult IBD patients (UC = 57 and CD = 13) (78). This analysis revealed increased levels of Streptococcus spp. and Enterobacteriaceae in UC patients, increased abundance of Veillonella spp. in CD patients, accompanied by depletion of Prevotella, Neisseria and Haemophilus spp. (78). Zhang et al. (2020) compared the salivary microbiome of CD patients (n = 29) with patients in remission (n = 31) and showed that active CD was associated with depletion of Neisseria, Haemophilus, Fusobacterium and Porphyromonas spp. compared to those patients in remission (79). Taken together, these sequence based studies show that oral dysbiosis occurs in IBD, although the exact nature of the dysbiosis characterized differs between studies. This may be due to the relatively small patient cohorts examined and the use of diverse anti-inflammatory medications in each group. In addition, in the context of pediatric IBD, none have exclusively focused on children and do not include longitudinal elements to determine if treatment is associated with reversal of dysbiosis. Despite these limitations, most studies concur that the genera Prevotella, Haemophilus and Veillonella are somehow affected in the oral cavity in IBD, which interestingly matches the genera shown to be enriched in the gut microbiota in CD patients (59). The possible link between changes in the oral microbiome and gut microbiota will be discussed further below.

The relationship between OFG oral CD is also under intense investigation and studies of the oral microbiome may indicate if these diseases have similar etiologies. Recently Goel et al. (2019) examined the salivary microbiome in 261 subjects comparing the oral microbiome of OFG patients and CD patients (including those with and without OFG) (80). A specific sequence type (oligotype) of S. salivarius was found to exhibit increased abundance in individuals with CD or OFG compared to controls and may have promise as an early biomarker of CD (80).

**ORAL-GUT MICROBIAL TRANSIT IN IBD?**

Recent studies of the gut microbiota in pediatric IBD patients have shown an increase in H. parinfluenza, Veillonellaceae, Neisseriaceae, and Fusobacteriaceae in CD patients (59) and H. parainfluenza and Veillonella spp. in UC patients (62). The increased abundance of these taxa in the gut environment may be the result of oral-gut transit. Despite the barrier of the acidic pH of the stomach, oral-gut transit of microorganisms is probably commonplace, as studies of probiotic bacteria show that microorganisms can transit from the oral cavity to the gut and remain viable (81). Auchtung et al. (82) also recently showed that yeast in the gut were acquired from the oral cavity and their levels in the gut were associated with dietary consumption (Saccharomyces) or poor oral hygiene (Candida).

Transit of these microorganisms from the oral cavity may disrupt host-microbiome homeostasis in the gut by displacing commensal SCFA producers. Additionally, some studies indicate that these oral taxa may be directly immunogenic. Previous studies have suggested that two of these bacterial taxa, H. parinfluenza and Veillonella spp. induce dendritic cell maturation, with the mature dendritic cells producing cytokines which may drive inflammation (83). Rothia mucilaginosa, a species associated with ulceration by Gevers et al. (59) can produce toxic levels of acetaldehyde in the presence of ethanol, which is a by-product of Enterobacterial fermentations (84). Rengarajan et al. (85) also showed significant antibody responses in the colon of IBD patients to bacteria normally found in the oral cavity including Gemella, Peptostreptococcus, and Streptococcus species.

Experimental evidence for the impact of oral gut transit in IBD patients was reported by Atashari et al. (86), who showed that inoculation of the oral microbiome from IBD children to C57BL/6 (B6) germ-free mice resulted in the accumulation of inflammatory IFN-g+ CD4+ TH1 cells. The gut microbiome of these mice was enriched in Fusobacterium, Veillonella and Klebsiella spp. Subsequent experiments showed that a Klebsiella pneumonia strain (Kp-2H7) recovered from the human salivary microbiota was the primary driver of the inflammatory TH1 cell responses, with marked accumulation of TH1 cells in the murine colon. These data clearly show that the oral cavity may be a reservoir for pathobionts, and that transit from the oral cavity to the gut may play a role in inducing inflammation in IBD patients (86).

**CONCLUSIONS AND FUTURE DIRECTIONS**

The understandable focus of IBD research to date on the intestinal microbiota has left much to be elucidated regarding the oral microbiome in patients with IBD. Transit of oral microorganisms likely happens in all children, but whether a genetic susceptibility to colonization with pathobionts exists in children with IBD, or whether such taxa are acquired secondarily is unknown. It is our hypothesis that oral-gut...
transit of *Veillonella*, *Klebsiella* or *Malassezia* spp. could trigger pathobiont-specific systemic responses that could induce inflammatory responses in the oral cavity resulting in oral manifestations of IBD (Figure 2). These systemic reactions may also account for the altered abundance of these species in the oral cavities of IBD patients. The specific nature of this response may make the oral cavity a useful source of biomarkers to diagnose and monitor treatment outcomes in IBD patients. Much of the existing data on the oral microbiome in IBD has come from patients already on various treatments. The effects of chronic treatments or periods of increased disease activity on oral microbial profiles have not yet been studied in sufficient detail. The “holy grail” of biomarker development based on oral sampling remains some time away, and yet would provide a more convenient, accessible and acceptable source for patients and clinicians than current blood or stool specimen-based assays.

**AUTHOR CONTRIBUTIONS**

KE, GPM, and SH all contributed to the literature survey, writing, and editing of the final review.

**FUNDING**

KE was supported by a scholarship from the Libyan Ministry of Education and Research. GPM was supported by the Irish Health Research Board (Grant No. ILP-POR-2019-030). SH was supported by the Irish National Children’s Research Centre (Grant Code C/18/2).

**REFERENCES**

1. Human Microbiome Consortium, Huttenhower C, Gevers D, Knight R, Abubucker S, Badger JH, et al. Structure, function and diversity of the healthy human microbiome. *Nature*. (2014) 486:207. doi: 10.1038/nature11234

2. Gevers D, Knight R, Petrosino JF, Huang K, McGuire AL, Birren BW, et al. The Human microbiome project: a community resource for the healthy human microbiome. *PLoS Biol*. (2014) 10:e1001377. doi: 10.1371/journal.pbio.1001377

3. Dave M, Higgins PD, Middha S, Rioux KP. The human gut microbiome: current knowledge, challenges, and future directions. *Transl Res J Lab Clin Med*. (2012) 160:246–57. doi: 10.1016/j.trsl.2012.05.003

4. Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. *PLoS Biol*. (2016) 14:e1002533. doi: 10.1371/journal.pbio.1002533

5. Grice EA, Segre JA. The human microbiome: our second genome. *Annu Rev Genom Hum Genet*. (2012) 13:151–70. doi: 10.1146/annurev-genom-090711-163814

6. Nash AK, Auchtung TA, Wong MC, Smith DP, Gesell JR, Ross MC, et al. The gut mycobiome of the human microbiome project healthy cohort. *Microbiome*. (2017) 5:153. doi: 10.1186/s40168-017-0373-4

7. Knight R, Callewaert C, Marotz C, Hyde ER, Debelsius JW, McDonald D, et al. The microbiome and human biology. *Annu Rev Genom Hum Genet*. (2017) 18:65–86. doi: 10.1146/annurev-genom-083115-022438
52. Crippa R, Zuccotti GV, Manteiga C. Oral manifestations of gastrointestinal diseases in children. Part 2: Crohn’s disease. Eur J Paediatr Dent Off J Eur Acad Paediatr Dent. (2016) 17:164–6. Available online at: http://admin.epjd.eu/download/EJPD_2016_2ClinicalAF.pdf

53. Katsanos KH, Torres J, Roda G, Biryo A, Deaporte E, Colombel J-F. Review article: non-malignant oral manifestations in inflammatory bowel diseases. Aliment Pharm Ther. (2015) 42:40–60. doi: 10.1111/apt.13217

54. Campbell H, Escudier M, Patel P, Nunes C, Elliott TR, Barnard K, et al. Distinguishing orofacial granulomatosis from Crohn’s disease; two separate disease entities. Inflamm Bowel Dis. (2011) 17:2109–15. doi: 10.1002/ibd.21599

55. James J, Patton DW, Lewis CJ, Kirkwood EM, Ferguson MM. Oro-facial granulomatosis and clinical atopy. J Oral Med. (1986) 41:29–30.

56. Patel P, Barone P, Nunes C, Bourrier L, O’Dell E, Escudier M, et al. Subepithelial dendritic B cells in orofacial granulomatosis. Inflamm Bowel Dis. (2016) 16:1651–160. doi: 10.1002/ibd.21169

57. Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, et al. Reduced diversity of faecal microbiota in crohn’s disease revealed by a metagenomic approach. Gut. (2006) 55:205–11. doi: 10.1136/gut.2005.073817

58. Joossens M, Huys G, Cnockaert M, Pretorius V, Verbeke K, Rutgeeters P, et al. The treatment-naive microbiome in new-onset crohn’s disease. Cell Host Microbe. (2014) 15:382–92. doi: 10.1016/j.chom.2014.02.005

59. Mouttawea W, Chiang C-K, Mühlbauer M, Ollendick T, et al. Altered intestinal microbiota–host mitochondria crosstalk in new onset Crohn’s disease. Nat Commun. (2016) 7:ncomm13419. doi: 10.1038/ncomms13419

60. Said HS, Suda W, Nakagome S, Chinen H, Oshima K, Kim S, et al. Dysbiosis of salivary microbiota in inflammatory bowel disease and its association with oral immunological biomarkers. DNA Res. (2014) 21:15–25. doi: 10.1093/dnares/dst037

61. Schirmmer M, Denson L, Vlamakis H, Franzosa EA, Thomas S, Gotman NM, et al. Composition and temporal changes in the gut microbiome of pediatric ulcerative colitis patients are linked to disease course. Cell Host Microbe. (2018) 24:600–10. doi: 10.1016/j.chom.2018.09.009

62. Seko P, Rigottier-Gois L, Gramet G, Sutren M, Pochart P, Butcher J, Abujamel T, et al. Altered intestinal microbiota–host mitochondria crosstalk in new onset Crohn’s disease. Nat Commun. (2013) 4:2522. doi: 10.1038/ncomms3527

63. Morgan XC, Tickle TL, Sokol H, Gevers D, Deveney KL, Ward DV, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Sci Transl Med. (2012) 12:R79. doi: 10.1126/scitranslmed.2012-13979

64. Shaw KA, Bertha M, Hofmekler T, Chopra P, Vatanen T, Srivatsa A, et al. Dysbiosis, inflammation, and response to treatment: a longitudinal study of pediatric subjects with newly diagnosed inflammatory bowel disease. Genome Med. (2016) 8:75. doi: 10.1186/s13073-016-0331-y

65. Limon JJ, Tang I, Li D, Wolf AJ, Michelsen KS, Funari V, et al. Malassezia is associated with crohn’s disease and exacerbates colitis in mouse models. Cell Host Microbe. (2019) 25:377–88.e6. doi: 10.1016/j.chom.2019.01.007

66. He J, Li Y, Cao Y, Xue J, Zhou X. The oral microbiome diversity and its relation to human diseases. Folia Microbiol. (2014) 60:69–80. doi: 10.1186/s12223-014-0342-2

67. Xun Z, Zhang Q, Xu T, Chen N, Chen F. Dysbiosis and ectotypes of the salivary microbiome associated with inflammatory bowel diseases and the assistance in diagnosis of diseases using oral bacterial profiles. Front Microbiol. (2018) 9:11.36. doi: 10.3389/fmicb.2018.01136

68. Zhang K, Yanai M, Morgan XC, Hwang H, Zhang C, Zhong J, Wang Z, et al. Dynamics of the salivary microbiome during different phases of crohn’s disease. Front Cell Microbiol. (2020) 10:544704. doi: 10.3389/fcmicro.2020.544704

69. Goel RM, Prosdocimi EM, Amar A, Omar Y, Escudier MP, Sanderson JD, et al. Streptococcus salivarius: a potential salivary biomarker for orofacial granulomatosis and crohn’s disease? Inflamm Bowel Dis. (2019) 25:azz022. doi: 10.1111/ibd.152865

70. Derrien M, Vlieg J van H. Fate, activity, and impact of ingested bacteria within the human gut microbiota. Trends Microbiol. (2015) 23:354–66. doi: 10.1016/j.tim.2015.03.002

71. Auchtung TA, Fofanova TY, Stewart CJ, Nash AK, Wong MC, Gesell JR, et al. Dynamics of the salivary microbiota during different phases of crohn’s disease. J Clin Gastroenterol. (2014) 48:513–23. doi: 10.1097/MCG.0000000000000305

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Elmaghrawy, Hussey and Moran. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.